NCT04772079: A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis
- State
- Under way
- Phase
- Phase 3
- People
- 153 planned
- Started
- 23 Mar 2021
- Primary completion
- 1 Jan 2029
- Arms
- Active treatment deucravacitinib standard dose, Active treatment deucravacitinib half-standard dose
- Results
- None posted
- 26 Feb 2021: Trial registered
- 23 Mar 2021: Trial started